Market Research Report
Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2019
|Published by||Global Markets Direct||Product code||363568|
|Published||Content info||58 Pages
Delivery time: 1-2 business days
|Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2019|
|Published: June 10, 2019||Content info: 58 Pages||
According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2019'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.
The report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2019' outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 6 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Women's Health, Gastrointestinal, Metabolic Disorders and Respiratory which include indications Lung Cancer, Breast Cancer, Colon Cancer, Endometriosis, Inflammatory Pain, Liver Cancer, Pain, Prostate Cancer, Allergies, Arthritis Pain, Autoimmune Disorders, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Esophageal Cancer, Familial Adenomatous Polyposis, Gastric Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Post-Operative Pain, Rectal Cancer, Rheumatoid Arthritis, Solid Tumor and Ulcerative Colitis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.